Literature DB >> 28275236

Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?

Gema Ruiz-Hurtado1, Luis M Ruilope1,2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275236     DOI: 10.1038/hr.2017.27

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  16 in total

1.  Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Authors:  Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong; Martin P Lefkowitz
Journal:  Lancet       Date:  2010-03-16       Impact factor: 79.321

2.  LCZ696, The Need for an Indication in Arterial Hypertension.

Authors:  Jose C Prado; Luis M Ruilope
Journal:  Am J Hypertens       Date:  2015-08-18       Impact factor: 2.689

3.  Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.

Authors:  Hiromi Rakugi; Takuya Tsuchihashi; Kazuyuki Shimada; Hirotaka Numaguchi; Chisato Nishida; Hiroya Yamaguchi; Masayoshi Shirakawa; Kyoichi Azuma; Kenji P Fujita
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

4.  Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.

Authors:  Ouppatham Supasyndh; Ningling Sun; Kazuomi Kario; Kudsia Hafeez; Jack Zhang
Journal:  Hypertens Res       Date:  2016-11-17       Impact factor: 3.872

Review 5.  Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.

Authors:  Chirag Bavishi; Franz H Messerli; Bernard Kadosh; Luis M Ruilope; Kazuomi Kario
Journal:  Eur Heart J       Date:  2015-04-21       Impact factor: 29.983

Review 6.  Current challenges in the clinical management of hypertension.

Authors:  Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

Review 7.  How can resistant hypertension be identified and prevented?

Authors:  Anna Solini; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2013-03-05       Impact factor: 32.419

8.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

Review 9.  Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.

Authors:  Julian Segura; Jorge Salazar; Luis M Ruilope
Journal:  Expert Opin Investig Drugs       Date:  2013-06-04       Impact factor: 6.206

10.  Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Authors:  Sadayoshi Ito; Minoru Satoh; Yuko Tamaki; Hiromi Gotou; Alan Charney; Naoko Okino; Mizuki Akahori; Jack Zhang
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.